1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
POLISH FINANCIAL SUPERVISION AUTHORITY |
|||||||||||
|
UNI - EN REPORT No |
4 | / |
2026 |
|
||||||
Date of issue: |
2026-01-29 |
||||||||||
Short name of the issuer |
|||||||||||
KRKA |
|||||||||||
Subject |
|||||||||||
2025 Krka Group Performance Estimate |
|||||||||||
Official market - legal basis |
|||||||||||
Art. 17 ust. 1 MAR |
|||||||||||
Unofficial market - legal basis |
|||||||||||
Contents of the report: |
|||||||||||
Based on the provisions of Article 26 of the Ljubljana Stock Exchange Rules, Article 158 of the Market in Financial Instruments Act and Article 17 of Regulation (EU) No 596/2014, Krka, d. d., Novo mesto (hereinafter: Krka) releases the 2025 unaudited performance estimates for the Krka Group. The press releases with 2025 Krka Group performance estimate is attached. This announcement will be published on the company’s website (www.krka.biz) starting from 29 January 2026, for a minimum period of 5 years. |
|||||||||||
Annexes |
|||||||||||
File |
Description |
||||||||||
2025 Krka Group performance estimatE |
|||||||||||
KRKA, TOVARNA ZDRAVIL D.D. |
|||||||||||||
(fullname of the issuer) |
|||||||||||||
KRKA |
Farmaceutyczny (far) |
||||||||||||
(short name of the issuer) |
(sector according to clasification of the WSE in Warsow) |
||||||||||||
8501 |
Nove Mesto |
||||||||||||
(post code) |
(city) |
||||||||||||
Smarjeska |
6 | ||||||||||||
(street) |
(number) |
||||||||||||
+386 7 331 21 11 |
+386 7 332 15 37 |
||||||||||||
(phone number) |
(fax) |
||||||||||||
(e-mail) |
(web site) |
||||||||||||
nie dotyczy |
|||||||||||||
(NIP) |
(REGON) |
||||||||||||
SIGNATURE OF PERSONS REPRESENTING THE COMPANY |
|||||
Date |
Name |
Position / Function |
Signature |
||
2026-01-29 |
Jože Colarič |
President of the Management Board and CEO |
|||
